| Date | Title | | | 06/03/19 | Data Presented at ASCO Shows Natera's Signatera Test Detects Immunotherapy Treatment Response in Metastatic Cancers| Results Support Use of New Blood Test as Surrogate Endpoint in Clinical Trials Assessing Immune Checkpoint Inhibitor Effectiveness
SAN CARLOS, Calif., June 3, 2019 /PRNewswire/ -- A new study demonstrates the ability of Natera's Signatera™ test to assess patient response to immunotherapy in the metastatic setting across multiple cancer types by detecting molecular traces of circulating tumor DNA (ctDNA) in the blood. The study was presented at the American Society of Clinical Oncology (ASCO... |
| | | 05/21/19 | Noridian Posts Favorable Draft Local Coverage Determination for Natera's Prospera™ Kidney Transplant Test| Represents Major Commercialization Milestone
SAN CARLOS, Calif., May 21, 2019 /PRNewswire/ -- Noridian, the Medicare Administrative Contractor (MAC) for California-based laboratories, has posted a favorable draft local coverage determination (LCD) for use of Natera's Prospera™ test to assess active rejection in kidney transplant recipients.
In its LCD, Noridian states, "Prospera is an effective, non-invasive method of assessing kidney allograft status wit... |
| | | 05/09/19 | Natera Reports First Quarter 2019 Financial Results| SAN CARLOS, Calif., May 9, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the first quarter ended March 31, 2019 and provided an update on recent business progress.
Recent Accomplishments & Highlights
Generated total revenues of $66.8 million in the first quarter of 2019 compared to $62.3 million in the first quarter of 2018... |
| | | 05/09/19 | New Blood Test Detects Colorectal Cancer Recurrence Up to 16.5 Months Earlier| JAMA Oncology Study Suggests Potential for Natera's Signatera Test to Guide Treatment Decisions After Surgery
SAN CARLOS, Calif., May 9, 2019 /PRNewswire/ -- A new clinical study shows that Natera's Signatera™ test identified colorectal cancer recurrence up to 16.5 months earlier than radiologic imaging by detecting traces of tumor DNA in the blood after surgery. The test also identified patients most likely to relapse, both before and after chemotherapy.1 Results were published in the May ... |
| | | 05/07/19 | Signatera™ Blood Test Detects Bladder Cancer Relapse Up to Eight Months Earlier Than Current Clinical Standards| Journal of Clinical Oncology Study Shows Natera's Test is Highly Prognostic and Effective for Recurrence Detection
SAN CARLOS, Calif., May 7, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) today announced the publication of a clinical validation study demonstrating that its Signatera™ molecular residual disease (MRD) test was highly prognostic of recurrence in patients with bladder cancer, and it identified recurrence up to 8.2 months earlier than current clinical standards with 100 perce... |
| | | 05/06/19 | FDA Grants Breakthrough Device Designation to Natera's Signatera Test| Accelerated Regulatory Review Intended to Expedite Use of Test in Pharmaceutical Trials and Improve Upon Current Clinical Standards
SAN CARLOS, Calif., May 6, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) today announced that the U.S. Food and Drug Administration (FDA) has granted "Breakthrough Device" designation for its Signatera™ test for use in the post-surgical detection and quantification of circulating tumor DNA (ctDNA) in the blood of patients previously diagnosed with certain ty... |
| | | 05/02/19 | Natera Announces First Quarter 2019 Earnings Conference Call| SAN CARLOS, Calif., May 2, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its first quarter ended March 31, 2019, after the market close on May 9, 2019. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities, and financial outlook.
Earnings Confe... |
| | | 04/17/19 | Natera Announces Pricing of Follow-On Offering| SAN CARLOS, Calif., April 17, 2019 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 5,263,158 shares of its common stock at a price to the public of $19.00 per share. Closing of the offering is expected to occur on April 23, 2019, subject to customary closing conditions. In addition, Natera has granted the underwriters a 30-day option to purchase up to an additional 789,473 shares of common s... |
| | | 04/16/19 | Natera Launches Proposed Follow-On Offering| SAN CARLOS, Calif., April 16, 2019 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $100,000,000 of shares of its common stock. In addition, Natera expects to grant the underwriters a 30-day option to purchase up to an additional $15,000,000 of shares of its common stock from Natera at the public offering price less the underwriting discount. The offering is subject to market and other con... |
| | | 04/16/19 | New Publication Validates Clinical Performance of Signatera for Recurrence Monitoring and MRD Assessment in Breast Cancer| Molecular Residual Disease Detected Up to Two Years Prior to Clinical Relapse, with Zero False Positives SAN CARLOS, Calif., April 16, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), Cancer Research UK, Imperial College London and the University of Leicester, today announced the publication of results of a clinical study demonstrating that the Signatera™ research-use-only (RUO) molecular residual disease (MRD) assay detected disease relapse up to two years earlier tha... |
| | | 04/10/19 | Natera Announces Plans to Commercialize Tumor Whole Exome Sequencing from Plasma| Represents Next Advancement in Company's Innovative Oncology ctDNA Program
SAN CARLOS, Calif., April 10, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) Natera, a leader in cell-free DNA testing, today announced plans to commercialize a research-use-only (RUO) service for whole exome sequencing (WES) of circulating tumor DNA, using plasma samples from patients with cancer. The new service is expected to be available in the second half of 2019.
The assay d... |
| | | 03/28/19 | Medicare Issues Draft Local Coverage Determination for Natera's New Prospera™ Kidney Transplant Rejection Test| Represents Major Reimbursement Milestone on Company's Path to Commercialization in 2019
SAN CARLOS, Calif., March 28, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Palmetto MolDx has issued draft local coverage determination (LCD) for use of the company's new Prospera donor-derived cell-free DNA (dd-cfDNA) test to detect active rejection in kidney transplant recipients.
This draft c... |
| | | 03/26/19 | Natera to Partner with AMAL Therapeutics on Clinical Trial Using Signatera MRD Test to Assess Treatment Response to Colorectal Cancer Vaccine| New Clinical Trial Adds to Growing Number of Studies Supporting Use of Signatera as a Potential Surrogate Endpoint
SAN CARLOS, Calif., March 26, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, will partner with AMAL Therapeutics on a clinical trial focused on stage IV colorectal cancer. This study adds to the growing number of pharmaceutical trials using Natera's Signatera™ molecular residual disease (MRD) assay as a biomarker to assess treatment ... |
| | | 03/12/19 | Natera Reports Fourth Quarter and Fiscal Year 2018 Financial Results| SAN CARLOS, Calif., March 12, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the fourth quarter and year ended December 31, 2018, and provided an update on recent business progress.
Recent Accomplishments & Highlights
Total revenue generated was $67.0 million in Q4 2018 and $257.7 million for the full year 2018, which repres... |
| | | 03/11/19 | Natera and BGI Genomics Announce $50M Partnership to Commercialize Signatera Oncology Test in China and to Develop Reproductive Health Tests in Select Markets on BGI's DNBseq™ Technology Platform| Partnership marks significant milestone for Natera in monetizing its Signatera MRD test and for BGI Genomics a strong endorsement of its DNBseq™ technology platform by a leader in cell-free DNA genetic testing
SAN CARLOS, Calif. and SHENZHEN, China, March 11, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA genetic testing, and BGI Genomics Co., Ltd., (300676.SZ), the largest cell-free DNA clinical testing laboratory in China and one of the world's leading ... |
| | | 03/06/19 | /C O R R E C T I O N -- Natera, Inc./| In the news release, Natera, Inc. Announces Fourth Quarter and Fiscal 2018 Earnings Conference Call, issued 05-Mar-2019 by Natera, Inc. over PR Newswire, we are advised by the company that the first paragraph, last sentence, as well as the 'Earnings Conference Call Information" section should read "4:30 p.m. ET (1:30 p.m. PT)" rather than "4 p.m. ET (1 p.m. PT)" as originally issued inadvertently. The complete, corrected release follows:
Natera, Inc. Announces Fourth Quarter and Fiscal 2018 E... |
| | | 03/05/19 | Natera, Inc. Announces Fourth Quarter and Fiscal 2018 Earnings Conference Call| Natera Also to Present at 39th Annual Cowen Healthcare Conference
SAN CARLOS, Calif., March 5, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA, today announced that it will release results for its fourth quarter and year ended December 31, 2018, after the market close on March 12, 2019. Natera will host a conference call and webcast at 4 p.m. ET (1 p.m. PT) to discuss its financial results, business activities, and financial outlook.
... |
| | | 02/22/19 | Natera Announces Publication of Analytical Validation Study Demonstrating Superior Precision of Its Kidney Transplant Rejection Assay| Core Technology Delivers Superior Analytical Performance, Underpins Outstanding Clinical Performance
SAN CARLOS, Calif., Feb. 22, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA, today announced analytical validation study results to be published online in the journal Transplantation demonstrating the superior performance of its donor-derived cell-free DNA (dd-cfDNA) test for detecting active rejection in kidney transplant recipients.1 The study showed superior a... |
| | | 02/19/19 | Natera Presents Outcomes Data at SMFM Annual Meeting Showing Strong Clinical Performance of Its SNP-Based Non-Invasive Prenatal Test| Study Shows High Positive Predictive Values in Detecting Common Chromosomal Aneuploidies in All Women, Including Women Under 35 Years of Age
SAN CARLOS, Calif., Feb. 19, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, presented data at the Society for Maternal-Fetal Medicine (SMFM) Annual Pregnancy Meeting showing strong clinical performance of its Panorama® SNP-based non-invasive prenatal test (NIPT) to detect common chromosomal aneuploidies (gen... |
| | | 02/01/19 | Natera Announces Agreement with One Lambda to Co-Distribute Its Kidney Transplant Rejection Test| Agreement Enhances Commercial Presence in Organ Transplant Centers
SAN CARLOS, Calif., Feb. 1, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of cell-free DNA, today announced a partnership with Thermo Fisher Scientific's One Lambda brand, a global leader in human leukocyte antigen (HLA) typing and antibody monitoring assays for transplantation, to co-distribute Natera's kidney transplant rejection test in the United States in col... |
| | | 01/07/19 | Natera Announces Publication of Kidney Transplant Validation Study, Demonstrating Superior Data in Detection of Clinical and Subclinical Rejection| Represents Successful Achievement of All 2018 Commercialization Milestones, on Path to 2019 Launch
SAN CARLOS, Calif., Jan. 7, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA, today announced clinical validation study results published in the Journal of Clinical Medicine,1 demonstrating the highly accurate performance of its donor-derived cell-free DNA (dd-cfDNA) test for active allograft rejection in kidney transplant recipients, including higher sensitivity and... |
| | | 01/04/19 | Natera To Webcast Live Presentation at the 37th Annual J.P. Morgan Healthcare Conference| SAN CARLOS, Calif., Jan. 4, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of cell-free DNA, today announced that it will webcast a live presentation at the 37th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday, Jan. 9, 2019, at 1:30 p.m. Pacific Time.
Natera's newly appointed CEO Steve Chapman and Executive Chairman Matthew Rabinowitz will provide... |
| | | 01/04/19 | Natera Obtains Z-Codes for Signatera MRD and Treatment Monitoring Test in Oncology| Represents Key Reimbursement Milestone In Line with Planned Clinical Launch
SAN CARLOS, Calif., Jan. 4, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in non-invasive genetic testing and cell-free DNA, today announced the assignment of two Z-codes for the company's Signatera™ test, in preparation for its planned clinical launch in Q2 2019. Signatera, when clinically available, is intended for use by oncologists to detect molecular residual disease (MRD) and monitor treatm... |
| | | 01/02/19 | Natera Appoints Steve Chapman CEO and Robert Schueren COO; Matthew Rabinowitz Moves to Executive Chairman| Proven Commercial Execution Selected for CEO Role; Seasoned Operational Expertise Selected for COO Role
SAN CARLOS, Calif., Jan. 2, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of cell-free DNA, has announced the appointment of Steve Chapman as Chief Executive Officer (CEO) effective today and Robert Schueren as Chief Operating Officer (COO) effective January 7, 2019. Previously, Chapman was the company's COO and will succeed Ma... |
| |
|
